Welcome to our dedicated page for Processa Pharmaceuticals news (Ticker: PCSA), a resource for investors and traders seeking the latest updates and insights on Processa Pharmaceuticals stock.
Processa Pharmaceuticals Inc (PCSA) is a clinical-stage biopharmaceutical company pioneering Next Generation Chemotherapy (NGC) treatments through advanced regulatory science. This dedicated news hub provides investors and industry professionals with timely updates on clinical developments, regulatory milestones, and strategic initiatives in oncology innovation.
Access comprehensive coverage of PCSA's progress in modifying FDA-approved cancer therapies, including trial results, partnership announcements, and scientific advancements. Our curated news collection features essential updates on pharmacokinetic optimization research, NGC pipeline developments, and regulatory submissions.
Key content includes analysis of treatment efficacy studies, executive leadership updates, and expert commentary on Processa's unique approach to enhancing existing oncology drugs. Stay informed about developments in chemotherapy modification techniques and their implications for cancer care standards.
Bookmark this page for verified updates on Processa's clinical programs and regulatory engagements. Check back regularly for objective reporting on biopharmaceutical innovations that balance scientific rigor with patient-focused therapeutic improvements.
Processa Pharmaceuticals (Nasdaq: PCSA), a clinical-stage pharmaceutical company, has provided significant updates on its product pipeline and business developments. The company has signed a binding term sheet with Intact Therapeutics for PCS12852, potentially worth up to $454 million in milestone payments plus 12% royalties and a 3.5% equity stake.
The company's lead oncology asset, PCS6422 (NGC-Cap), is actively enrolling patients in a Phase 2 study for metastatic breast cancer, with interim analysis expected in H2 2025. For PCS499, Processa is designing a new adaptive pivotal Phase III study for rare kidney diseases and establishing a dedicated subsidiary to enhance strategic flexibility.
In portfolio optimization moves, Processa has terminated the PCS3117 license agreement, while continuing to explore development strategies for PCS11T, their preclinical oncology asset. The company has also strengthened its balance sheet with a $7 million capital infusion.
Processa Pharmaceuticals (Nasdaq: PCSA) has announced that Dr. David Young, Founder and President of Research & Development, will present at the World Orphan Drug Congress USA 2025 in Boston. The presentation, scheduled for April 24, 2025, at 2:00 p.m. ET, will focus on 'Applying Principles of FDA's Project Optimus to Oncology and Non-Oncology Rare Diseases'.
Dr. Young will discuss how Project Optimus principles can be utilized to determine optimal dosing for improved efficacy and safety in rare disease treatments, both oncological and non-oncological. This approach aligns with Processa's Regulatory Science strategy, which aims to enhance therapeutic outcomes through improved regulatory science methodologies.
Processa Pharmaceuticals (Nasdaq: PCSA), a clinical-stage pharmaceutical company specializing in next-generation cancer therapies, has announced its participation in the upcoming MedInvest Biotech and Pharma Investor Conference. The event will take place on March 27-28, 2025, at Cooley's law office in New York City.
The company's management team will deliver a corporate overview presentation on March 28th at 9:40 a.m. Eastern time. Additionally, they will engage in one-on-one meetings with registered investors and conference attendees throughout the event. The presentation materials will be made accessible on Processa's website.
Processa Pharmaceuticals (Nasdaq: PCSA), a clinical-stage pharmaceutical company developing next-generation cancer therapies, has announced its participation in the 2025 BIO CEO & Investor Conference. The event will take place on February 10-11, 2025, at the New York Marriott Marquis.
The company's management will deliver a corporate overview presentation on Tuesday, February 11 at 10:00 a.m. Eastern time in the Plymouth Room. Throughout the conference, management will be available for one-on-one meetings with registered investors and attendees. Interested parties can schedule meetings through the BIO Partnering portal, while those unable to attend can contact Yvonne Briggs at Alliance Advisors to arrange meetings with management.
Processa Pharmaceuticals (PCSA) has completed its previously announced public offering, raising $5 million in gross proceeds. The offering included 8,050,672 shares of common stock (or pre-funded warrants) with accompanying Series A warrants to purchase up to 8,050,672 shares and Series B warrants for up to 4,025,336 shares.
The offering price was set at $0.615 per share for institutional investors and $0.7975 for the Company's CEO and board members. Notable participants included the Company's CEO, board members, existing institutional investors, and a healthcare-focused institutional investor. A.G.P./Alliance Global Partners served as the sole placement agent for the offering, which was conducted under a Form S-1 registration statement declared effective on January 27, 2025.
Processa Pharmaceuticals (PCSA) has announced the pricing of a $5 million public offering, featuring 8,050,672 shares of common stock with accompanying warrants. The offering includes participation from the company's CEO, board members, existing institutional investors, and a healthcare-focused institutional investor.
The offering is priced at $0.615 per share for institutional investors and $0.7975 for company insiders, with both Series A and Series B warrants included. Series A warrants allow purchase of up to 8,050,672 shares at $0.65 per share with a five-year term, while Series B warrants cover 4,025,336 shares at $0.65 per share with an eighteen-month term.
The closing is expected around January 29, 2025, with A.G.P./Alliance Global Partners acting as sole placement agent. The company must seek stockholder approval within 90 days for the issuance of shares upon warrant exercise.
FAQ
What is the current stock price of Processa Pharmaceuticals (PCSA)?
What is the market cap of Processa Pharmaceuticals (PCSA)?
